Table 2

Unadjusted OR for treatments, testing and in-hospital outcomes comparing women with men according to age

	All patients		Age group, year
	Women (n=3574) Per cent	Men (n=8412)	<60 (n=3914)	60–69 (n=3213) OR*	70–79 (n=3562)	≥80 (n=1297)
Acute medications
Aspirin≤24 h	83.9	Men (n=8412)	87.5	60–69 (n=3213) OR*	70–79 (n=3562)	≥80 (n=1297)	0.83	0.75†	0.90	0.90
Clopidogrel≤24 h	51.5	56.6	0.80†	0.81†	0.86†	1.01
β-Blocker≤24 h	43.8	48.5	0.87	0.84†	1.06	0.98
ACE-I/ARB‡	60.2	63.8	0.90	0.88	0.90	0.73†
Statin‡	73.0	75.2	0.79†	0.85†	1.02	1.02
Reperfusion therapies ≤24 h
Primary PCI	8.5	12.8	0.54†	0.85	0.81	0.76
Fibrinolytic therapy	18.9	24.7	0.88	0.88	0.87	1.00
Any reperfusion	27.4	37.5	0.68†	0.84†	0.82†	0.86
Staged procedures
Cardiac catheterisation	18.8	28.8	0.72†	0.68†	0.71†	0.64†
PCI	8.6	13.9	0.84	0.67†	0.66†	0.59
CABG	0.34	0.61	0.58	0.41	1.02	–
Any revascularisation	8.9	14.4	0.84	0.64†	0.67†	0.59
Testing
Troponin	48.9	49.9	0.85	0.90	0.96	1.06
Echocardiogram	46.1	52.6	0.97	0.67†	0.90	0.93
In-hospital outcomes
Death‡	12.5	6.7	2.29†	2.21†	1.20	1.38
Death‡ + withdrawal from treatment	17.2	9.1	2.20†	2.21†	1.37†	1.25
Death within 24h	5.5	2.9	1.75	2.21†	1.34	1.89†
Composite complications	15.3	11.8	1.46†	1.21	1.17	1.29
Major bleeding	0.8	1.0	0.22	0.74	1.07	0.44
Length of stay (days)
<8	29.5	22.7	1.03	0.73†	1.07	1.21†
8–11	20.9	24.0	1.35†	0.87	0.89	0.96
12–15	21.4	23.4	1.22†	1.06	0.87	0.88
≥16	28.2	29.8	1.60†	0.83	1.07	0.62†

*The OR is for the comparison of women with men.
†The OR is significant between women and men.
‡During hospitalisation.
ACE-I/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor blocker; Composite complication: recurrent MI, cardiac shock, cardiac arrest, congestive heart failure and ischaemic stroke; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention.